**Composition**
Each suppository contains 5mg of Hydrocortisone (micronized), 5mg of Eutectic Acetic acid and 5mg of Framycetin Sulphate (micronized).

**Pharmaceutical Form**
Suppositories: Off-white, torpedo-shaped homogenous suppositories.

**Pharmacological Properties**
A combination of glucocorticoid, local anesthetic and antibacterial.

**Pharmacokinetics**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal or external hemorrhoids, and such hemorrhoidal complications as fissures, prolapses, perianal eczema, and post-operative states.

**Dosage and method of administration**
Dosage: Application into the rectum, twice daily and after each bowel movement (every time you empty your bowel). Treatment should last for a week.

**Contraindications**
- Patients hypersensitive to the active ingredients or any of the excipients.
- Undesirable effects
Like all medicines Proctosedyl suppositories may cause some problems, although these are rare such as itching, pain or rash that may develop around the back passage.

**Special warnings and precautions for use**
- Special precautions for storage
If you accidentally take too many suppositories or swallow one by mistake, supportive treatment is required.

- Prolonged use of anti-infectives may result in the development of super-infection similar to thrush and super/ficial vascular dilation.

- Continuous application without interruption will result in local atrophy of the skin, and growth retardation.

- Under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.

**Therapeutic indications**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pregnancy and lactation**
These are rare such as itching, pain or rash that may develop around the back passage.

**Dosage:**
In the local management of pain, pruritus and inflammation associated with internal hemorrhoids (every time you empty your bowel). Treatment should last for a week.

**Contraindications:**
- In children under the age of three years because of the possibility of adrenocortical suppression.

**Pharmaceutical Form**
Suppoctire AM (hard fat)

**Hydrochloride (micronized), 10mg of Aesculin (micronized) and 10mg of Framycetin.**

**Special precautions for storage**
Not applicable.
Plant: CAIRO- EGYPT
Packaging material code: E042762
Packaging material name: Pamph Proctosedyl Supp S@n
Second packaging material code: 40996
VISTAlink folder number: 1004707
VISTAlink PDF version: 2

This document has been digitally signed by the following people within the VISTAlink system, following the sanofi-aventis group guidelines.

<table>
<thead>
<tr>
<th>Reason</th>
<th>Signed by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market marketing validation</td>
<td>Mohamed Fawzy (Egypt marketing department team)</td>
<td>19/12/2012 08:03:17</td>
</tr>
<tr>
<td>Market medical affairs validation</td>
<td>Tamer Talaat (Egypt medical affairs team)</td>
<td>19/12/2012 08:27:34</td>
</tr>
<tr>
<td>Market regulatory validation</td>
<td>Nermeen Nassar (Egypt regulatory affairs team)</td>
<td>20/12/2012 12:01:44</td>
</tr>
<tr>
<td>Plant final technical validation</td>
<td>Gamal Habib (Cairo packaging team)</td>
<td>20/12/2012 12:14:50</td>
</tr>
<tr>
<td>Plant quality validation</td>
<td>Madlen Samir (Cairo quality assurance team)</td>
<td>30/12/2012 14:25:03</td>
</tr>
<tr>
<td>Plant ready to print</td>
<td>Gamal Habib (Cairo packaging team)</td>
<td>08/01/2013 13:23:09</td>
</tr>
</tbody>
</table>